A concept for a Japanese regulatory framework for emerging medical devices with frequently modified behavior.

Clicks: 353
ID: 101540
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #4 of 6 articles by views in clinical and translational science

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Recent progress in the Internet of Things and artificial intelligence has made it possible to utilize the vast quantity of personal health records, clinical data, and scientific findings for prognosis, diagnosis, and therapy. These innovative technologies provide new possibilities with the development of medical devices (MDs), whose behaviors can be continuously modified. A novel regulatory framework covering these MDs is now under discussion in Japan. In this review, we introduce the regulatory initiative for MDs, and importance of a paradigm shift from regulation to innovation regarding MDs.
Reference Key
ota2020aclinical Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ota, Nagomi;Tachibana, Keisuke;Kusakabe, Tetsuya;Sanada, Shoji;Kondoh, Masuo;
Journal clinical and translational science
Year 2020
DOI
10.1111/cts.12784
URL
Keywords
Deep learning artificial intelligence proton therapy synthetic ct brain mri gan structure

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.